Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. (Q38959812)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Walter Klepetko

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Karin Schelch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Mir A Hoda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Julia Münzker

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Tamas Garay

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Ulrike Setinek

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Martin Filipits

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Edgar Selzer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Jozsef Tovari

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Szilvia Torok

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Istvan Kenessey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Klaus Holzmann

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Bettina Grasl-Kraupp

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Brigitte Marian

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Walter Berger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

English

0 references

publication date

1 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Respiratory and Critical Care Medicine

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

190

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

763-772

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

The European mesothelioma epidemic

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

The epidemiology of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Advances in malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Malignant pleural mesothelioma: surgical roles and novel therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Alpha-tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor autocrine loop: mechanism and the role of oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

FGF18 in colorectal tumour cells: autocrine and paracrine effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Fibroblast growth factors and their receptors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Nedd4-1 binds and ubiquitylates activated FGFR1 to control its endocytosis and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Crosstalk between mTOR complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

Malignant pleural mesothelioma: when is radiation therapy indicated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

N-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate co-receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201404-0658OC

10.1164/RCCM.201404-0658OC

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25188816%20AND%20SRC:MED&resulttype=core&format=json